You are viewing Diagnostic technology

The Molecular Diagnostics in Oncology market size is based on a triangulation methodology which is primarily based on experimental modeling approaches such as patient-level data or disease epidemiology for all key indications, number of procedures and analysis of the installation base for any equipment in order to obtain accurate market estimates for the base year as well as in the analysis of historical data. A bottom-up approach is always used to obtain relevant molecular diagnostic data in oncology for specific countries / regions. Country-specific data is re-analyzed to derive data at the global level. Specific factors / parameters are considered to be related to the individual oncology molecular diagnostics market and quantified with insightful rationale.

A comprehensive estimate of the molecular diagnostics in oncology market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the Molecular diagnostics sales in oncology during the forecast period. The comparison of prices by region with the world average price is also taken into account in the study.

Click here for a sample report (including full table of contents, table and figures): –https://www.factmr.com/connectus/sample?flag=S&rep_id=6864

Key segments covered by molecular diagnostics industry research in oncology

• By product

  • Molecular diagnostic reagents and kits in oncology
  • Molecular diagnostic instruments in oncology
    • Molecular diagnostic table instruments in oncology
    • Portable and PoC instruments for molecular diagnostics in oncology
  • Molecular diagnostic software and services in oncology

• By technology

  • Polymerase chain reaction (PCR) in oncology Molecular diagnostics
  • Isothermal nucleic acid amplification technology (INAAT) for molecular diagnostics in oncology
  • DNA sequencing and next-generation sequencing (NGS) for molecular diagnostics in oncology
  • In situ hybridization (ISH) technology for molecular diagnostics in oncology
  • DNA microarrays and DNA microarrays for molecular diagnostics in oncology

• By end user

  • Molecular diagnostics in oncology used in diagnostic laboratories
  • Molecular diagnostics in oncology used in hospitals and clinics

Analysts have used many leading industry-wide business intelligence tools to consolidate market facts, figures and data into revenue estimates and projections in Market Insights of Oncology Molecular Diagnostic.

Major market stakeholders including industry players, policy makers and investors from various countries have continuously realigned their strategies and approaches to implement them in order to take advantage of new opportunities.

Need more information on the reporting methodology? Click here:-https://www.factmr.com/connectus/sample?flag=RM&rep_id=6864

Key points of the market research

• The global molecular diagnostics in oncology market is expected to grow 2.3 times in value by 2031.
• The demand for reagents and kits will increase at a CAGR of 12.8% over the next ten years.
• The Chinese market is expected to reach a valuation of US $ 670 million by 2031.
• The markets in Japan and Canada are expected to grow 8% and 9%, respectively.
• The demand for PCR diagnostic technology will dominate the market over the next ten years.

The key parameters analyzed during the estimation of the molecular diagnostics in oncology market include:

• Analyze Drugs / Therapeutic Field in Oncology Molecular Diagnosis:Overall population by age group / prevalence or incidence of any disease / treatment seeking rate / dosing regimen / average duration of treatment / overall cost of treatment and reimbursement are taken into account.
• To analyze consumables for molecular diagnostics in oncology:

Overall population / disease prevalence or incidence / treatment request rate / average duration of treatment / average number of devices used per patient / average number of procedures per device / average selling price per device / reimbursement are taken into account.

• To analyze molecular diagnostic equipment in oncology:

Number of health facilities (hospitals / outpatient surgical centers / clinics, etc.)

The average number of devices installed per installation / device lifespan / equipment replacement rate / new equipment sales per year / average sales price per equipment are taken into account.

Some of the insights and estimates of Molecular Oncology Diagnostics Market that makes this study unique in approach and effective in guiding stakeholders in understanding growth dynamics. The study provides:

• Details regarding the latest innovations and developments in molecular diagnostics in oncology and how it is gaining popularity with customers during the forecast period.
• Analysis of customer demand for products and how it is likely to evolve in the years to come.
• Latest regulations enforced by government agencies and local agencies and their impact on oncology molecular diagnostics market demand.
• Information on the adoption of new technologies and its influence on the size of the Molecular Diagnostics in Oncology market.
• Overview of the impact of COVID-19 on the molecular oncology diagnostics market and the economic disruption caused by the pandemic.
• Assesses the post-pandemic impact on Molecular Oncology Diagnostics market sales during the forecast period.

To Get Complete Insights on the Regional Landscape of Molecular Diagnostics in Oncology Market, Purchase Now: –https://www.factmr.com/checkout/6864

Competitive landscape

Leading oncology molecular diagnostic service providers, in an attempt to achieve stability, are adopting strategies such as specialty product development. The main players in the molecular diagnostics in oncology market are also entering into collaborations with the main brands of molecular diagnostic instruments in oncology, for the development of companion diagnostics relating to cancer.

Some of the key developments are:

• In September 2015; Roche has launched the Cobas EGFR v2 mutation assay, used for the diagnosis of non-small cell lung cancer (NSCLC), which is expected to drive the growth of this market.
• Qiagen and Lilly announced their intention to jointly develop companion diagnostics to target cancer biomarkers.
• In February 2019, ICON plc, a US-based biotechnology company, acquired MolecularMD for an undisclosed amount. The acquisition enhances ICON’s laboratory offering in molecular diagnostic testing and provides ICON with extensive test platforms, including next-generation sequencing and immunohistochemistry (IHC).

Read more trend reports from Fact.MR: – https://www.biospace.com/article/oral-antivirals-manufacturers-reliant-on-viral-and-chronic-diseases-drug-discovery-for-future-expansion-fact-mr/

How Fact.MR helps take strategic action for the Molecular Oncology Diagnostics Market Manufacturer?

• The data provided in the Molecular Oncology Diagnostics market report offers a comprehensive analysis of significant industry trends. Industry players can use this data to strategize their potential trade movements and generate remarkable revenue over the coming period.
• The report covers price trend analysis and value chain analysis as well as the analysis of the diverse supply of market players. The primary motive for this report is to help companies make data-driven decisions and strategize for their trade movements.

More related reports by Fact.MR on Health sector :

Veterinary endodontics market : _Forecast, trend analysis and competition monitoring – Global review 2021 to 2031

Therapeutic Support Surfaces Market: – Forecasts, trend analysis and monitoring of the competition – Global review 2021 to 2031

Computer Assisted Orthopedic Surgery Market : – Forecasts, trend analysis and monitoring of the competition – Global review 2021 to 2031

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1000 companies trust us to make their most critical decisions. We have offices in the United States and Dublin, while our global headquarters are in Dubai. While our experienced consultants use the latest technology to extract hard-to-find information, we believe our USP is the trust clients have in our expertise. Covering a wide spectrum – from automotive and industry 4.0 to healthcare and retail, our coverage is extensive, but we make sure that even the most specialized categories are analyzed. Contact us with your goals, and we will be a competent research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Office 400
Rockville, Maryland 20852
United States
Phone. : +1 (628) 251-1583
E-mail: [email protected]

The head office:
Unit No .: AU-01-H Gold Tower (AU),
Plot number: JLT-PH1-I3A,
Jumeirah Lakes Tours,
Dubai, United Arab Emirates

Visit our website: https://www.factmr.com

The post office The demand for PCR diagnostic technology to continue the upward trend in the molecular oncology diagnostics market, according to Fact.MR appeared first on Latest market reports.

Seegene Inc., South Korea’s largest point-of-service diagnostic kit manufacturer, will mark another milestone in popularizing molecular diagnostic technology with an advanced polymerase chain reaction (PCR) machine in time. real to detect various viruses, including Covid variants in the clinical ward, helping authorities respond more quickly to the spread of the virus.

The new test called AIOS will be presented for the first time at the opening of the American Association for Clinical Chemistry (AACC) to be held in Atlanta from September 26 to 30, according to sources close to the company on Thursday.

The AACC houses the latest technology and information on various diagnostic equipment, reagents, and test methods. Seegene, whose annual sales reached $ 1 billion last year, is one of the most notable companies among this year’s AACC presenters.

According to the sources, AIOS can perform the entire process of molecular diagnostics, such as nucleic acid extraction, PCR testing, and reading of results, with one system after sample collection.

Depending on the type of reagents, AIOS can detect up to 10 types of viruses including Covid-19 variants at the same time, or up to 15 types of respiratory viruses except Covid viruses. It weighs about a third less than the bulky all-in-one PCR equipment that weighs 1 to 1.5 tonnes. The new equipment comes in the form of a separate set into two compact devices to allow transport and installation in small clinics.

Sales are expected to start worldwide at the start of the new year. Seegene will mark its 20th anniversary with the launch of AIOS which will make advanced molecular diagnostics available in most small and medium-sized hospitals and neighborhood clinics which account for 39% of patient beds compared to 9% of large hospitals in Korea, according to the sources.

By Kim Si-gyun and Minu Kim

[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]

The Molecular Diagnostics in Oncology market size is based on a triangulation methodology which is primarily based on experimental modeling approaches such as patient-level data or disease epidemiology for all key indications, number of procedures and analysis of the installation base for any equipment in order to obtain accurate market estimates for the base year as well as in the analysis of historical data. A bottom-up approach is always used to obtain relevant molecular diagnostic data in oncology for specific countries / regions. Country-specific data is re-analyzed to derive data at the global level. Specific factors / parameters are considered to be related to the individual oncology molecular diagnostics market and quantified with insightful rationale.

A comprehensive estimate of the molecular diagnostics in oncology market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the Molecular diagnostics sales in oncology during the forecast period. The comparison of prices by region with the world average price is also taken into account in the study.

Click here for a sample report (including full table of contents, table and figures): –https://www.factmr.com/connectus/sample?flag=S&rep_id=6864

Key segments covered by molecular diagnostics industry research in oncology

• By product

  • Molecular diagnostic reagents and kits in oncology
  • Molecular diagnostic instruments in oncology
    • Molecular diagnostic table instruments in oncology
    • Portable and PoC instruments for molecular diagnostics in oncology
  • Molecular diagnostic software and services in oncology

• By technology

  • Polymerase chain reaction (PCR) in oncology Molecular diagnostics
  • Isothermal nucleic acid amplification technology (INAAT) for molecular diagnostics in oncology
  • DNA sequencing and next-generation sequencing (NGS) for molecular diagnostics in oncology
  • In situ hybridization (ISH) technology for molecular diagnostics in oncology
  • DNA microarrays and DNA microarrays for molecular diagnostics in oncology

• By end user

  • Molecular diagnostics in oncology used in diagnostic laboratories
  • Molecular diagnostics in oncology used in hospitals and clinics

Analysts have used many leading industry-wide business intelligence tools to consolidate market facts, figures and data into revenue estimates and projections in Market Insights of Oncology Molecular Diagnostic.

Major market stakeholders including industry players, policy makers and investors from various countries have continuously realigned their strategies and approaches to implement them in order to take advantage of new opportunities.

Need more information on the reporting methodology? Click here:-https://www.factmr.com/connectus/sample?flag=RM&rep_id=6864

Key points of the market research

• The global molecular diagnostics in oncology market is expected to grow 2.3 times in value by 2031.
• The demand for reagents and kits will increase at a CAGR of 12.8% over the next ten years.
• The Chinese market is expected to reach a valuation of US $ 670 million by 2031.
• The markets in Japan and Canada are expected to grow 8% and 9%, respectively.
• The demand for PCR diagnostic technology will dominate the market over the next ten years.

The key parameters analyzed during the estimation of the molecular diagnostics in oncology market include:

• Analyze Drugs / Therapeutic Field in Oncology Molecular Diagnosis:Overall population by age group / prevalence or incidence of any disease / treatment seeking rate / dosing regimen / average duration of treatment / overall cost of treatment and reimbursement are taken into account.
• To analyze consumables for molecular diagnostics in oncology:

Overall population / disease prevalence or incidence / treatment request rate / average duration of treatment / average number of devices used per patient / average number of procedures per device / average selling price per device / reimbursement are taken into account.

• To analyze molecular diagnostic equipment in oncology:

Number of health facilities (hospitals / outpatient surgical centers / clinics, etc.)

The average number of devices installed per installation / device lifespan / equipment replacement rate / new equipment sales per year / average sales price per equipment are taken into account.

Some of the insights and estimates of Molecular Oncology Diagnostics Market that makes this study unique in approach and effective in guiding stakeholders in understanding growth dynamics. The study provides:

• Details regarding the latest innovations and developments in molecular diagnostics in oncology and how it is gaining popularity with customers during the forecast period.
• Analysis of customer demand for products and how it is likely to evolve in the years to come.
• Latest regulations enforced by government agencies and local agencies and their impact on oncology molecular diagnostics market demand.
• Information on the adoption of new technologies and its influence on the size of the Molecular Diagnostics in Oncology market.
• Overview of the impact of COVID-19 on the molecular oncology diagnostics market and the economic disruption caused by the pandemic.
• Assesses the post-pandemic impact on Molecular Oncology Diagnostics market sales during the forecast period.

To Get Complete Insights on the Regional Landscape of Molecular Diagnostics in Oncology Market, Purchase Now: –https://www.factmr.com/checkout/6864

Competitive landscape

Leading oncology molecular diagnostic service providers, in an attempt to achieve stability, are adopting strategies such as specialty product development. The main players in the molecular diagnostics in oncology market are also entering into collaborations with the main brands of molecular diagnostic instruments in oncology, for the development of companion diagnostics relating to cancer.

Some of the key developments are:

• In September 2015; Roche has launched the Cobas EGFR v2 mutation assay, used for the diagnosis of non-small cell lung cancer (NSCLC), which is expected to drive the growth of this market.
• Qiagen and Lilly announced their intention to jointly develop companion diagnostics to target cancer biomarkers.
• In February 2019, ICON plc, a US-based biotechnology company, acquired MolecularMD for an undisclosed amount. The acquisition enhances ICON’s laboratory offering in molecular diagnostic testing and provides ICON with extensive test platforms, including next-generation sequencing and immunohistochemistry (IHC).

Read more trend reports from Fact.MR: – https://www.biospace.com/article/oral-antivirals-manufacturers-reliant-on-viral-and-chronic-diseases-drug-discovery-for-future-expansion-fact-mr/

How Fact.MR helps take strategic action for the Molecular Oncology Diagnostics Market Manufacturer?

• The data provided in the Molecular Oncology Diagnostics market report offers a comprehensive analysis of significant industry trends. Industry players can use this data to strategize their potential trade movements and generate remarkable revenue over the coming period.
• The report covers price trend analysis and value chain analysis as well as the analysis of the diverse supply of market players. The primary motive for this report is to help companies make data-driven decisions and strategize for their trade movements.

More related reports by Fact.MR on Health sector :

Veterinary endodontics market : _Forecast, trend analysis and competition monitoring – Global review 2021 to 2031

Therapeutic Support Surfaces Market: – Forecasts, trend analysis and monitoring of the competition – Global review 2021 to 2031

Computer Assisted Orthopedic Surgery Market : – Forecasts, trend analysis and monitoring of the competition – Global review 2021 to 2031

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1000 companies trust us to make their most critical decisions. We have offices in the United States and Dublin, while our global headquarters are in Dubai. While our experienced consultants use the latest technology to extract hard-to-find information, we believe our USP is the trust clients have in our expertise. Covering a wide spectrum – from automotive and industry 4.0 to healthcare and retail, our coverage is extensive, but we make sure that even the most specialized categories are analyzed. Contact us with your goals, and we will be a competent research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Office 400
Rockville, Maryland 20852
United States
Phone. : +1 (628) 251-1583
E-mail: [email protected]

The head office:
Unit No .: AU-01-H Gold Tower (AU),
Plot number: JLT-PH1-I3A,
Jumeirah Lakes Tours,
Dubai, United Arab Emirates

Visit our website: https://www.factmr.com

The post office The demand for PCR diagnostic technology to continue the upward trend in the molecular oncology diagnostics market, according to Fact.MR appeared first on Latest market reports.

Vancouver Island grocers are teaming up with the BC Cancer Foundation for an initiative that could save lives.

They are looking to raise $ 500,000 to advance life-saving diagnostic technology that will change outcomes for prostate cancer patients in the community and beyond.

From September 8 to November 8, the Future Cures campaign will bring together local grocery brands from across the island.

Coalition partners include: 49th Parallel Grocer, Country Grocer, Fairway Markets, Quality Foods, Thrifty Foods, and Tru Value Foods.

Thrifty Foods will match all donations up to $ 125,000 through November 8.

This campaign will raise funds for PSMA-PET: an advanced imaging technology used to optimize and inform the treatment of patients with prostate cancer.

PSMA imaging scans help pinpoint the location of prostate cancer and reveal whether it has spread.

PSMA-PET funding will help make this breakthrough technology a future standard of care in British Columbia

While it varies from location to location, some stores accept in-person donations, some make a percentage of sales, some combine online donations, some host events, and some accept donations directly at the cashier.

This year, more than 6,000 people on Vancouver Island will be diagnosed with cancer. Prostate cancer is the most common prostate cancer in men.

To donate, click here.

Vancouver Island grocers are teaming up with the BC Cancer Foundation for an initiative that could save lives.

They are looking to raise $ 500,000 to advance life-saving diagnostic technology that will change outcomes for prostate cancer patients in the community and beyond.

From September 8 to November 8, the Future Cures campaign will bring together local grocery brands from across the island.

Coalition partners include: 49th Parallel Grocer, Country Grocer, Fairway Markets, Quality Foods, Thrifty Foods, and Tru Value Foods.

Thrifty Foods will match all donations up to $ 125,000 through November 8.

This campaign will raise funds for PSMA-PET: an advanced imaging technology used to optimize and inform the treatment of patients with prostate cancer.

PSMA imaging scans help pinpoint the location of prostate cancer and reveal whether it has spread.

PSMA-PET funding will help make this breakthrough technology a future standard of care in British Columbia

While it varies from location to location, some stores accept in-person donations, some make a percentage of sales, some link donation online, some host events, and some accept donations directly at checkout.

This year, more than 6,000 people on Vancouver Island will be diagnosed with cancer. Prostate cancer is the most common prostate cancer in men.

To donate, click here.

Business journalist

TELECOM giant Econet Wireless Zimbabwe said it has installed monitoring diagnostic tools to reduce revenue leakage and network fraud in accordance with the latest regulations under Statutory Instrument 95 of 2021.

Guided by the Telecommunications Traffic Monitoring and Revenue Assurance Regulations (Statutory Instrument 95/2021), the Postal and Telecommunications Regulatory Authority of Zimbabwe (Potraz), has the mandate to establish a non-electronic system. intrusive that allows the regulator to independently monitor and account for national and international telecommunications traffic and revenues.

The intervention aims to combat network fraud, enforce billing integrity and improve revenue assurance for regulatory and tax purposes.

In a statement accompanying the results for the fiscal year ended February 28, 2021, Econet welcomed the World Bank’s digital economy diagnostic report for Zimbabwe, which was launched in June 2021.

While the report ranks Zimbabwe as “advanced” in its provision of infrastructure and connectivity services due to the pioneering efforts of the group and its affiliates, Econet said there was room for further improvements.

“Econet has already installed its own traffic monitoring diagnostic tools to prevent revenue leakage and traffic fraud,” the company said.

The telecommunications giant said it was still in consultation with Potraz on the implementation of SI95 / 2021, adding that it welcomes the priority given to the development of the digital economy as part of the National Strategy for development 1 (NDS1).

The five-year master plan, which succeeded the Transitional Stabilization Program, sets out policies, institutional reforms and national priorities from 2021 to 2025 for the country to achieve an upper middle-income economy by 2030.

“We believe that we already have and can continue to make a significant contribution to national efforts. The rural population remains underserved in the new digital economy and we are always looking for relevant low cost solutions to address this segment in line with the government’s development agenda, ”the company said.

He said the availability of foreign currency continues to be the biggest obstacle it faces and this has limited the ability to provide adequate capacity to its customers.

“The company encountered operational challenges in meeting its needs for capacity improvement and routine maintenance.

“We remain hopeful that improvements in the availability of foreign currency through the interventions of fiscal and monetary authorities will improve this situation for the foreseeable future,” he said.

“Our main tariffs were last revised in August 2020. In view of the inflationary pressures undergone, we believe that another tariff revision is due to keep the sector viable.

“All of our prices are determined by the regulator using given cost inputs. The timely adjustment of tariffs, using the telecommunications price index, is essential to the sustainability of our business. “

However, consistent and high-quality grid power supply remained a challenge during the reporting period, which is why the company used diesel generators to supplement what was pulled from the national grid.

“As a result, we continue to see an increase in our carbon footprint as well as the cost of our operations. We continue to work to improve our ecological footprint and reduce carbon emissions by increasing the number of solar-powered base station sites, ”said Econet.

The Soros Economic Development Fund (SEDF), founded by George Soros, with support from the Bill & Melinda Gates Foundation and several philanthropic investors, has announced the launch of Global Access Health (GAH), a social enterprise that will seek to expand access to affordable medical technology.

As part of this initiative, the group financed the acquisition of the British company Mologic, a developer of lateral flow and rapid diagnostic technologies.

GAH members will invest at least £ 30million ($ 41million) in the deal.

WHY IS IT IMPORTANT

Mologic is developing tests that can help fight tropical diseases such as dengue fever, bilharzia and river blindness, as well as COVID-19.

SEDF’s investments in GAH and GAD are part of a portfolio of recent investments made in support of Open Society Foundations’ commitment to expanding global access to affordable public health products and technologies.

The initiative will aim to achieve this goal through decentralized research, development and manufacturing in and for the countries of the South.

The transaction will give the project the capacity to fill gaps in the provision of global diagnostics in low-income communities and regions.

“Testing, or diagnostics, is essential for daily public health needs, to enable physicians and healthcare professionals to provide patients with appropriate treatment as early as possible,” said Roxana Bonnell, public health expert at the Open Society Foundations. “As we saw during the COVID-19 pandemic, access to testing is absolutely essential to contain the spread of contagious diseases, an issue that ultimately affects us all.”

THE BROADER CONTEXT

Recently, Indian healthcare solutions provider HealWell24, together with actress and philanthropist Gul Panag, launched their latest web platform which provides a space for connection between doctors and patients.

ON THE RECORD

Sean Hinton, CEO of SEDF, said: “The COVID-19 pandemic has painfully demonstrated the fundamental inequalities in global public health, and in particular the critical importance of access in low- and middle-income countries to low and high prices. Quality diagnostic tools that save lives. In this unique transaction, philanthropic funds and investors work together with a knowledgeable and visionary management team in a truly innovative way to address at least part of this failure by allowing a leading commercial enterprise to focus all of its resources on solving one of the world’s most pressing public health problems.

Mark Davis, CEO of Mologic, said: “Mologic’s transition to a social enterprise is a deliberate, logical and natural step for a company focused on delivering affordable diagnostics and biotechnology to places that have been underserved by the world. relentless pursuit of profitability. With the support of our shareholders, donors and partners, we have come a long way; we believe we have the right people and skills for the challenges and opportunities ahead. And we hope this unique transaction will be an example for others to follow.

“Your efforts under bridges were undoubtedly exhausting.”

–Caledon Hockley, Titanic, 1997

I once heard of a patient who developed red, edematous patches on the skin of her face that looked a lot like the lesion in her face. this photo. It was first treated as shingles and got worse. It was eventually biopsied and called cutaneous lymphoid hyperplasia. A number of different treatments have been tried without any improvement. He was biopsied again, same result. This time, they performed molecular genetic analysis by PCR for a rearrangement of the immunoglobulin heavy chain gene. The result, which took more than a month to return: polyclonal cutaneous lymphoid hyperplasia. Eventually, when nothing else worked, it was treated with radiation, responded beautifully like lymphomas do, and never came back.

Previously, his doctors would have looked at the clinical presentation, seen the infiltration of B cells on the pathology, called it cutaneous lymphoma, and treated accordingly, skipping almost 2 years of other management which resulted in no improvement. from this the patient’s condition.

I don’t know what I’m trying to say about this except that sometimes our new fancy tools fail us. Testing with immunohistochemistry and genetic analysis can be incredibly powerful tools in the fight against cancer. They can also lead to weeks of procrastination as the patient’s face falls. They undoubtedly avoid many situations where the patient would get the wrong treatment for what they really got, but if used improperly they can also really delay the right treatment. Time is healing.

It reminds me of a funny story from my days in the Navy. Back when Admiral (then Captain) Hyman G. Rickover was able to convince Congress to put incredibly expensive nuclear reactors in Navy ships, he was faced with a difficult dilemma: Should he take Navy ship operators and try to teach them nuclear physics, or take nuclear physicists and try to make them naval officers? He chose the latter, and to maintain quality control, personally interviewed each of them before hiring him, to the tune of tens of thousands of job interviews over the next 24 years.

The decision caused another dilemma, however. Nuclear physicists tend to get deeply involved in solving the puzzles inherent in their work. Everyone was concerned that those egg heads in the “hole” (engine room) at the bottom of the ship would focus on minor details of their surroundings, such as incoming enemy missiles, in their zeal to solve a mystery of the ship. engineering or another. The result of this concern was that each Nuke had to learn to drive the ship, so that he could imagine exactly how tense the situation on the deck must be as he worked to recover the engines / electrical system / launch catapults. planes. online again. And so it was, comrades, that yours truly learned to steer a ship the size of the Empire State Building and filled to the brim with over 5,000 of his closest friends. Turns out I’m pretty good at it and stayed there for 2 years after that, in addition to my main job with reactors.

The parallel I’m trying to draw here is that I sometimes feel like catching my diagnostic friends for as long as it takes to start treatment, just to jog their memory a little as to the state of affairs in the- above decks. But then the cooler, more rational part of my brain takes over. I would prefer that they do their job without such distractions. They really are a great team and they work very hard.

Please join the discussion below, but if you need to communicate with me offline, you can reach me at [email protected]

Follow Medscape on Facebook, Twitter, Instagram, and Youtube

Philanthropists George Soros and Bill Gates are part of a consortium that buys a UK developer of testing technology that they plan to turn into a social enterprise capable of rapidly and inexpensively diagnosing tropical diseases in low-income countries.

The group, led by the Soros Economic Development Fund, will invest at least £ 30million in Mologic, a developer of lateral flow tests, including those used for Covid-19.

In an unusual deal, Mologic, a for-profit company based in Bedford in the south-east of England, was purchased so that it could focus on manufacturing low-cost diagnostics for tropical diseases such as dengue and river blindness.

Mologic was co-founded by Professor Paul Davis, one of the creators of the original ClearBlue pregnancy test, and his son Mark. It will be renamed “Global Access Health”.

Mark Davis, Managing Director of Mologic, said it was time for people to put Africa first, not to leave it as “Ariadne’s sons”.

“The only way to do more was to disconnect from the unbridled profits,” he said.

He said a rapid antigen test was a “fantastic piece of very simple technology, where all the intellect is hidden in plain sight”. Precision rates were improving dramatically and could eventually approach those of molecular tests, he added.

Along with SEDF, the investment arm of Soros’ Open Society Foundations, the Bill & Melinda Gates Foundation is also supporting the takeover of the British company whose current owners are Foresight Group LLP and Calculus Capital. Other philanthropists also participate.

Sean Hinton, managing director of SEDF, said the new company would try to address a “classic market failure” in which the industry had failed to make testing widely available in low-income countries. Instead, he had focused on a “high cost, high impact” physician-led model in developed economies that could not be easily replicated across the world, he added.

Describing it as a “buyout for good,” Hinton said the Mologic deal was the first time the foundation has used this model. “We took out the venture capital, removed the need for return on equity, but it will continue to operate like a business,” he said.

Mologic worked with a Senegalese research institute to test a 10-minute Covid-19 diagnostic, with the goal of ultimately doing it for $ 1. Its sister company Global Access Diagnostics, also a stake in the buyout, has received millions of pounds in funding from the UK to expand manufacturing of the Covid-19 lateral flow tests.

The company’s Covid-19 tests have received CE certification, so they can be deployed by a professional in Europe, but are not yet adopted by Public Health England or approved in the United States.

Covid-19 has shown how lateral flow diagnostics can be used far beyond pregnancy tests, inexpensively to track infectious disease.

Dan Wattendorf, director of innovative technology solutions at the Gates Foundation, said the pandemic had been a “bugle call” about the importance of access to diagnostics. He said if Mologic’s social business model is successful, its use could be explored in other areas.

“The community’s lack of access to affordable and effective diagnostics for COVID – or other high-risk diseases – results in an inability to detect the disease and allocate resources to break chains of transmission,” did he declare.

SEATTLE – (COMMERCIAL THREAD) – Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, today announced that it has been granted an additional patent for its Bio-RFID ™ technology, bringing its significant portfolio of patents to 57 issued and pending patents, a important step for the company.

“We are building a revolutionary technology platform that will revolutionize medical diagnostics, starting with what we believe to be the world’s first non-invasive glucose monitoring device,” said Phil Bosua, CEO of Know Labs and inventor of Bio- RFID. “This patent is essential because without the ability to control the timing of the frequency capture, precise non-invasive measurements using radio frequency on the human body are not possible. We have obtained 22 patents to date and 35 more are pending. Our advancements will lead to breakthroughs in diagnosis and potentially disease prevention, so we pursue and implement a disciplined intellectual property strategy to protect our innovative technology and its value. “

US Patent No. 11,033,208 was issued by the United States Patent and Trademark Office and is titled “Fixed Run Time Frequency Scans for an Analyte Sensor”. The patent relates to how the operation of Know Labs’ Bio-RFID sensor technology is controlled. The detection routines conducted by the sensor to non-invasively detect an analyte in the body are conducted substantially identically to each other, which means that the results are obtained under conditions as close to the same as possible. This allows for a more accurate comparison between the results of each detection routine, increasing the precision and accuracy of Know Labs’ Bio-RFID sensor technology to non-invasively measure and identify a variety of analytes, including the glucose.

Know Labs recently reported the positive results of an independent preclinical study validating the company’s Bio-RFID technology. This recently issued patent demonstrates the accuracy and sensitivity of the sensor, which is required to pass FDA clinical trials for the company’s non-invasive blood glucose meter.

Know Labs will continue to align its product development efforts with its intellectual property strategy. The company continues to file new patents on a regular basis and will provide further details on the scope and scope of its intellectual property portfolio as the patents are issued.

About Know Labs, Inc.

Know Labs, Inc. is a public company whose shares trade under the ticker symbol “KNWN”. The Company’s technology uses spectroscopy directing electromagnetic energy through a substance or material to capture a unique molecular signature. The Company calls its technology Bio-RFID ™. Bio-RFID technology can be integrated into a variety of portable, mobile, or benchtop form factors. This patented and patent-pending technology enables efficient performance of analyzes that previously could only be performed by invasive and / or expensive and time-consuming laboratory tests. The first application of our Bio-RFID technology will be in a product marketed as a glucometer. It will provide the user with real-time information on their blood sugar. This product will require approval from the United States Food and Drug Administration prior to its market introduction.

Safe Harbor Declaration

This press release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and section 27A of the Securities Act of 1933, as amended, and section 21E of the Securities Exchange Act of 1934, as as modified. These statements appear in several places in this release and include all statements that are not statements of historical fact concerning the intention, belief or current expectations of Know Labs, Inc., its directors or officers in this regard. which concerns, inter alia: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) product performance. You can identify these statements by using the words “may”, “will”, “could”, “should”, “should”, “plans”, “expects”, “plans”, “continues”, “” Project “,” intention “,” probable “,” forecast “,” probable “,” potential “and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that these forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the control of Know Labs, Inc., and actual results may differ materially from those projected in the forecast forward-looking statements due to various factors. These risks and uncertainties also include additional risk factors as discussed in documents filed by the Company with the United States Securities and Exchange Commission, including its annual report on Form 10-K for the year ended 30 September 2020, Forms 10-Q and 8 -K, and in other documents that we make from time to time with the Securities and Exchange Commission. These documents are available in the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date of their publication. The Company assumes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20210622005332/en/